Viridian is able to undertake independent evaluation of the technical risk inherent in new bioscience ventures targeting plant and microbial commercial opportunities. We can reassure investors that current IP assets contribute exceptional value to the business rather than squandering invested funds.
Viridian can assess the value of an IP portfolio to a growing business and identify opportunities to reduce patent costs without damaging value growth. We can identify and evaluate potential FTO issues well before formal analysis by IP counsel.
For bioscience companies in turn-around or liquidation, Viridian can identify value in non-essential or residual IP assets that may be recouped through licensing or sale.